With the antigen expressed in yeast from a cDNA clone encoding a non-structural region of newly discovered hepatitic C virus (HCV) genome, the prevalence of HCV antibody in people in Thailand was investigated. Antibody was detected in 2.6% of healthy blood donors and in 2.8% of healthy pregnant women. These prevalence rates were higher than those reported previously from Japan, USA and European countries. Among community-acquired, sporadic cases of acute and chronic non-A, non-B hepatitis, however, only 5.7% and 15.4% were shown to possess the antibody, respectively. Among hepatocellular carcinoma patients who were negative for hepatitis B surface antigen in the sera, 11.1% had antibody to HCV. These seroepidemiological data suggest that HCV plays an important role as an etiological agent in Thailand; however, other agents must also be involved in etiologic agents of viral hepatitis and chronic liver disease.
(Received March 5, 1990 . Accepted May 17, 1990) SUMMARY:
With the antigen expressed in yeast from a cDNA clone encoding a non-structural region of newly discovered hepatitic C virus (HCV) genome, the prevalence of HCV antibody in people in Thailand was investigated. Antibody was detected in 2.6% of healthy blood donors and in 2.8% of healthy pregnant women. These prevalence rates were higher than those reported previously from Japan, USA and European countries. Among community-acquired, sporadic cases of acute and chronic non-A, non-B hepatitis, however, only 5.7% and 15.4% were shown to possess the antibody, respectively. Among hepatocellular carcinoma patients who were negative for hepatitis B surface antigen in the sera, 11.1% had antibody to HCV. These seroepidemiological data suggest that HCV plays an important role as an etiological agent in Thailand; however, other agents must also be involved in etiologic agents of viral hepatitis and chronic liver disease.
INTRODUCTION
More than 90% of transfusion-associated hepatitis cases in the world are caused neither by hepatitis A nor hepatitis B viruses (1) (2) (3) (4) . After a long and extensive search for the etiological agent(s) for non-A, non-B hepatitis (NANBH), a cDNA clone expressing a protein which specifically reacts with sera from chronically infected NANBH patients was obtained.
The cDNA was later identified to be derived from the 10 kb genome of an RNA virus now termed hepatitis C virus (HCV) (5) . Serological assays to detect antibody to a nonstructural gene product of the virus (anti-HCV) performed in the USA, Japan and Italy have shown that HCV is a major causative agent for transfusionassociated NANBH (6) (7) (8) (9) . In these countries, more than 50% of NANBH patients with no history of blood transfusion have been shown to have anti-HCV. This suggests that HCV is also associated with cases of sporadic or communityacquired NANBH.
We have conducted a sero-survey to examine the prevalence of anti-HCV in a population where multiple agents play an etiological role in development of hepatitis. In Thailand, viral hepatitis is one of the major public health problems (10) . The annual summary of the Ministry of Public Health in 1985 reported the annual incidence of viral hepatitis to be 34.6 cases per 100,000 population (10).
Among these cases, 37.9% were caused by hepatitis A and 43.3% by hepatitis B.
The rest were designated as NANBH. A recently discovered hepatitis E virus is considered to play an important role as a causative agent for NANBH in Asian countries including Thailand (11) . We have examined the prevalence of anti-HCV among Thai people to know the etiological significance of HCV in sporadic, community-acquired hepatitis cases in an area where multiple viral agents are associated in the development of hepatitis.
MATERIALS AND METHODS
Serum collection: Five groups of sera were collected; Group 1 included sera from 390 healthy blood donors. Blood in this series were collected, examined and used for transfusion at Thai Red Cross Institute in August in 1989. They were of course all negative for hepatitis B virus surface antigen (HBsAg) and their alanine aminotransferase (ALT) levels were below 35 units. Group 2 consisted of sera from 212 healthy pregnant women visiting the Thai Navy Hospital during October to December in 1988. Group 3 sera were from 35 acute cases of NANBH . These sera were collected during May to October in 1988 at Vajira Hospital and Chantabur Hospital in Bangkok. The diagnosis of NANBH was based on clinical features and the exclusion of HAV and HBV infections by the absence of specific serum markers. Group 4 sera were from 13 chronic NANBH patients at National Cancer Institute, Bangkok. All sera were examined to exclude infections of HAV , HBV and cytomegalovirus. None of these patients had previously received blood transfusions.
Group 5 included sera from 47 randomly selected patients with hepatocellular carcinoma who were hospitalized at National Cancer Institute .
Serological tests: HBsAg was tested by the reverse passive hemagglutination test, HBsAb by the passive hemagglutination test and HBeAg by the reverse passive hemagglutination test. Anti-HAV was tested by the enzyme linked immunosorbent assay (ELISA). Anti-HCV was assayed by the ELISA technique with Chiron kits provided by Ortho-Diagnostics of Japan. Briefly, a part of non-structural region (NS3/NS4) of HCV cDNA was expressed in yeast in the form of a fused polypeptide with human superoxide dismutase (C100-3) (6) . After extensive purification, the antigen was fixed onto microtiter plate wells to capture circulating anti-HCV in serum specimens. Specific antigen-antibody complexes were bound to murine anti-human IgG monoclonal antibody conjugated with horseradish peroxidase.
After addition of the o-phenylenediamine-dihydrochrolide substrate, the bound conjugates were oxidized and their optical density (OD) measured with a microwell reader. Sera with OD values over the cut-off values determined according to the manufacturer's instruction were considered positive. RESULTS 
AND DISCUSSION
To determine the prevalence of anti-HCV among healthy people in Thailand, we assayed 390 healthy blood donor serum samples . These sera were from blood used for transfusion in the Bangkok and all negative for HBs antigen.
Their alanine aminotransferase levels were below 35 Karmen units . As shown in Table I , 10 of 390 donors had anti-HCV. The male and female ratio reflected the actual blood donation during the period of the study and no sex difference in anti-HCV positivity was found.
We expanded the study to analyze 212 samples from healthy pregnant women collected in a hospital in Bangkok area. Their ages ranged from 18 to 35
with an average of 21.5 years. Six of the 212 pregnant women were positive for anti-HCV (Table II) . The prevalence of anti-HCV was similar or even lower in The prevalence of anti-HCV among these two healthy groups suggested that HCV carrier rate is about 2.6-2.8%. This is higher than the values reported previously from Japan, USA and European countries ranging 0.5-1.5% (6, 8, 9, (12) (13) (14) (15) by the use of the same assay system described here. In Thailand, 3.1% of the population under the age of 30 were positive, whereas only 0.45% of the normal population of those ages in Japan had HCV antibody (K. Nishioka, personal communication).
The observed higher prevalence of HCV antibody is not Table III .
Anti-HCV in sera from acute and chronic non -A , non-B hepatitis patients in Thailand Table IV . Anti-HCV in 47 hepatocellular carcinoma patients consistent with the low incidence of post-transfusion NANBH in Thailand , which was reported to be 0.5% (16) . The reasons for this are not known , but the lack of precise nationwide surveillance for NANBH may be responsible for the underestimated incidence.
We examined HCV antibody among patients clinically diagnosed as NANBH. None of these patients had a previous history of blood transfusion . Two of 35 (5.7%) sera collected at acute phases were positive for HCV antibody , while two of 13 patients (15.4%) in chronic phases had anti-HCV (Table III) . Although the numbers were small, anti-HCV positivities among both acute and chronic cases of clinically diagnosed community-acquired (sporadic) NANBH were lower than those observed previously in Japan and other countries . In Thailand, HCV plays a significant role as an etiological agent for NANBH, but some other agent(s) may also be involved for the development of the disease. 
